구조모아 (StructureMoa)항암 chemical structure spider web
방문Merck SharpDohme LLC
Corticosteroid(Merck Sharp & Dohme LLC)은 Carcinoma, Non-Small-Cell Lung 표적 치료제로, Carcinoma, Non-Small-Cell Lung 영역에서 개발·상용화 중입니다. 작용기전: binds to an inactive glucocorticoid receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: ORR 5.6% (ClinicalTrials.gov NCT02472366). 차별점: novel treatments have been invented and analyzed, it is unclear that any of them will take the position of ICSs as the first,.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Carcinoma, Non-Small-Cell Lung
Carcinoma, Non-Small-Cell Lung
Recruiting
2026-09-02
Data Confidence · Low
Development Signal · Emerging
CAR T-cell product type, and higher day 0 C-reactive protein were
novel treatments have been invented and analyzed, it is unclear that any of them will take the position of ICSs as the first,
binds to an inactive glucocorticoid receptor
immune-mediated condition of the gastrointestinal tract with highly variable treatment responses
apoptosis, pyroptosis, and ferroptosis), and activation of pro-fibrotic cascades most notably TGF-β1/Smad2/3, NF-κB,
biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu
resistance to the effects of Dex was observed, as evidenced by the absence of changes in the glycemic curve peak, AUC, or rate of dec
구조화 데이터
mouse, mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Merck SharpDohme LLC
Corticosteroid(Merck Sharp & Dohme LLC)은 Carcinoma, Non-Small-Cell Lung 표적 치료제로, Carcinoma, Non-Small-Cell Lung 영역에서 개발·상용화 중입니다. 작용기전: binds to an inactive glucocorticoid receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: ORR 5.6% (ClinicalTrials.gov NCT02472366). 차별점: novel treatments have been invented and analyzed, it is unclear that any of them will take the position of ICSs as the first,.
공개된 구조화 근거가 제한적입니다.
구조화 데이터
Carcinoma, Non-Small-Cell Lung
Carcinoma, Non-Small-Cell Lung
Recruiting
2026-09-02
Data Confidence · Low
Development Signal · Emerging
CAR T-cell product type, and higher day 0 C-reactive protein were
novel treatments have been invented and analyzed, it is unclear that any of them will take the position of ICSs as the first,
binds to an inactive glucocorticoid receptor
immune-mediated condition of the gastrointestinal tract with highly variable treatment responses
apoptosis, pyroptosis, and ferroptosis), and activation of pro-fibrotic cascades most notably TGF-β1/Smad2/3, NF-κB,
biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu
resistance to the effects of Dex was observed, as evidenced by the absence of changes in the glycemic curve peak, AUC, or rate of dec
구조화 데이터
mouse, mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.